Citigroup’s Plus Therapeutics PSTV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $74 | Sell |
17
-3,703
| -100% | -$20.2K | ﹤0.01% | 5529 |
|
|
2026
Q1 | $15.1K | Buy |
3,720
+1,782
| +92% | +$13.5K | ﹤0.01% | 4905 |
|
|
2025
Q4 | $24.8K | Buy |
+1,938
| New | +$29.2K | ﹤0.01% | 4808 |
|
|
2025
Q2 | – | Sell |
-6
| Closed | -$139 | – | 5848 |
|
|
2025
Q1 | $139 | Buy |
+6
| New | +$168 | ﹤0.01% | 5427 |
|
|
2023
Q4 | – | Sell |
-23
| Closed | -$776 | – | 5826 |
|
|
2023
Q3 | $776 | Buy |
+23
| New | +$1.24K | ﹤0.01% | 5131 |
|
|
2019
Q4 | – | Sell |
-90
| Closed | -$115K | – | 7770 |
|
|
2019
Q3 | $115K | Buy |
+90
| New | +$325K | ﹤0.01% | 5569 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 7352 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 7697 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 7801 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 7203 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 7144 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 6554 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 6511 |
|
|
2014
Q3 | – | Hold |
0
| – | – | – | 6564 |
|
|
2014
Q2 | – | Hold |
0
| – | – | – | 6176 |
|
|
2014
Q1 | – | Hold |
0
| – | – | – | 5663 |
|
|
2013
Q4 | – | Hold |
0
| – | – | – | 5356 |
|
|
2013
Q3 | – | Hold |
0
| – | – | – | 5470 |
|
|
2013
Q2 | – | Hold |
0
| – | – | – | 5830 |
|
Other funds holding PSTV
Citigroup's PSTV Position: Q2 2026 in Review
Citigroup reduced its Plus Therapeutics (PSTV) stake by 100% in Q2 2026, selling an estimated $20.2K and leaving 17 shares worth $74. The position accounts for ﹤0.01% of the portfolio, ranked #5529.
Citigroup first reported a position in PSTV in Q3 2019 and has held it in 6 quarters since. The position peaked at $115K in Q3 2019. 4 funds tracked by Wall St. Rank hold PSTV as of Q2 2026.
- Citigroup held 17 shares of Plus Therapeutics worth $74 as of Q2 2026.
- Citigroup sold 3,703 Plus Therapeutics shares in Q2 2026, an estimated $20.2K.
- Plus Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5529 holding.
- Citigroup first reported a position in Plus Therapeutics in Q3 2019 and has held it in 6 quarters since.
- Citigroup's Plus Therapeutics position peaked at $115K in Q3 2019.
- 4 funds tracked by Wall St. Rank held Plus Therapeutics as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.